The product is a Pharma Grade API suite for artemether and lumefantrine, supplied as separate active pharmaceutical ingredients for tablet, capsule, granule, and injectable processing. Artemether conforms to the current USP and Ph. Int. monographs, and lumefantrine conforms to the current Ph. Int. and IP monographs. The model is a two-API system: artemether is suitable for oral fixed-dose combination tablets, capsules, and granules as well as intramuscular injection, while lumefantrine is suitable only for oral fixed-dose combination products because of its very low aqueous solubility. The standard fixed-dose oral tablet contains 20 mg artemether and 120 mg lumefantrine per unit; artemether therefore represents approximately 5–10% w/w of the total core mass in common formulation designs. Artemether is an oil-soluble sesquiterpene lactone derivative with a short elimination half-life of approximately 2–3 h, whereas lumefantrine is an aryl amino alcohol with a terminal elimination half-life of approximately 3–6 days. Both APIs have poor aqueous solubility, and lumefantrine oral absorption increases with dietary fat. Release of the APIs is controlled by high-performance liquid chromatography under monograph conditions, with residual solvents evaluated according to USP <467> and ICH Q3C. The two APIs are separately micronized, classified, and then blended or granulated by the finished-dose manufacturer. This separation is necessary because artemether and lumefantrine differ in particle-size distribution, bulk density, and moisture sensitivity, and co-milling may alter polymorphic form or accelerate degradation.

For the oral fixed-dose combination, the pharmacopoeial identity of each API must be confirmed by infrared absorption spectrophotometry against the reference standard, and impurity profiling is performed by gradient HPLC. The artemether monograph controls related substances including dihydroartemisinin, which is the principal hydrolytic degradation product. The lumefantrine monograph controls its specified related substances; limits are not harmonised, so the current monograph must be consulted. The API grade for oral dosage forms should be selected according to particle-size distribution, bulk density, and flow index rather than assay alone. A narrowly distributed laser-diffraction particle size report is used to set the milling endpoint. Supplier certificates typically report D10, D50, and D90 values, but these are not pharmacopoeially fixed. Finished-dose manufacturers must justify the selected particle size by content uniformity, dissolution, and bioavailability data. Residual water is controlled to avoid artemether hydrolysis; loss on drying at USP <731> is commonly specified at ≤0.5%, although supplier limits may differ. The API is released under ICH Q7 good manufacturing practice and should be accompanied by a certificate of analysis stating the actual batch results, not only the specification limits.

What Limits Direct Compression of 20:120 Artemether–Lumefantrine Tablets?

Direct compression of the 20:120 blend is limited by particle-size mismatch, poor flowability, and segregation during transfer from a bin blender to a rotary tablet press. Artemether is present as the low-mass component, and differences in bulk density between the two APIs can produce assay non-uniformity under USP <905> uniformity-of-dosage-units testing. Lumefantrine has low bulk density and shows electrostatic adhesion to metal surfaces; in a rotary press fitted with a force feeder, this behaviour can lead to weight variation and punch filming. A lubricant concentration of 0.25–0.5% w/w magnesium stearate is typical, but mixing beyond approximately 5 min can reduce tablet tensile strength by coating the granules with a hydrophobic layer. Wet granulation is therefore preferred over direct compression for many production lines. In a high-shear granulator, purified water or an aqueous binder is added under impeller and chopper control to densify the blend. The wet mass is dried in a fluid-bed dryer at an inlet-air temperature below the artemether melting point of approximately 86–88°C to avoid partial melting and to limit thermal degradation. The dried granule is milled through a screen with an aperture size of 0.8–1.5 mm, then blended with extragranular disintegrant such as crospovidone or sodium starch glycolate. Tablet compression targets a crushing strength of 50–100 N unless a higher hardness is required for film coating. The lower melting point of artemether is a defined processing boundary; it precludes hot-melt extrusion at barrel temperatures above 80°C unless a cooled extruder is used. Final granule moisture is controlled to below 2.0% w/w to minimise hydrolytic degradation to dihydroartemisinin. Published data for a single universal direct-compression design are limited; batch-scale compaction studies are required because the two APIs exhibit different yield pressures and elastic recovery.

For oral granules and capsule filling, wet granulation or moisture-activated dry granulation is used instead of direct compression. A preblend of artemether, lumefantrine, and an intragranular filler such as microcrystalline cellulose or pregelatinized starch is processed in a high-shear granulator. The granulating fluid is added at a rate that maintains product temperature below 40°C and produces a densified granulate with sufficient flow for capsule filling. Fluid-bed drying is controlled by outlet air temperature and final moisture rather than by fixed drying time. The dried granules are sized with an oscillating mill, and extragranular disintegrant is blended in a low-shear tumble mixer for 10–20 min. For capsule filling, dosator or auger systems are adjusted to the granulate bulk density and flow index; material with bulk density below approximately 0.4 g/mL often requires densification before encapsulation. Filled capsules may be band-sealed if the moisture barrier of the shell is insufficient. Residual moisture is confirmed below the finished-product limit because artemether can hydrolyse to dihydroartemisinin; that degradation product is quantified by a validated HPLC method under the artemether monograph. Residual solvent testing is performed according to USP <467> or equivalent Ph. Eur. <2.4.24>, and microbial limits are assessed under USP <61> and USP <62>. Equipment parameters are batch-scale dependent and cannot be transferred directly across production lines without revalidation.

Lumefantrine Is Excluded from Parenteral Formulations by Aqueous Solubility and Food-Dependent Absorption

Artemether can be formulated as an intramuscular injection in an oily vehicle, typically sesame oil or refined groundnut oil, at a strength of 80 mg/mL. The injectable-grade artemether requires tighter control of particle size, residual solvents, and pyrogen levels; bacterial endotoxin limits are assessed under USP <85>, and particulate matter is controlled under USP <788>. The oily vehicle must meet its compendial monograph for identity, viscosity, peroxide value, and acid value, because the vehicle influences drug release from the intramuscular depot. Lumefantrine is not formulated as an injectable because its aqueous solubility is below practical parenteral formulation limits and its oral absorption is dependent on dietary fat; an injectable formulation would require cosolvent or lipid-emulsion concentrations exceeding safe osmotic and hemocompatibility boundaries. For severe malaria, treatment typically begins with injectable artesunate or artemether, followed by oral artemether–lumefantrine tablets as the continuation phase. The term “Oral & Injectable” in the product description therefore applies to artemether as a single API, not to lumefantrine; the combination product is an oral tablet, capsule, or granule dosage form. This distinction differs from artesunate-containing parenteral products, which are prepared as aqueous solutions for intravenous or intramuscular administration.

During film coating, the tablet bed temperature is typically kept below 55°C to avoid thermal stress on artemether and to prevent sticking. The coating dispersion is applied at a spray rate that maintains the bed below the glass transition of the coating polymer and below the artemether melting point. The final tablets are packaged in aluminium/aluminium or aluminium/PVC/PVDC blisters with a desiccant because both APIs, especially the fixed-dose blend, are sensitive to moisture and light. Container moisture permeability is evaluated under USP <671> for containers. Stability is assessed under ICH Q1A(R2) at long-term conditions of 25°C/60% RH and accelerated conditions of 40°C/75% RH for at least 6 months; shelf-life assignment requires additional real-time data from the selected packaging configuration. Published stability data for a specific supplier formulation may be limited, so each production site must generate its own stability profile from the finished dosage form.

Pharmacopoeial Release Limits for Assay, Related Substances, and Elemental Impurities

The following release matrix summarises the compendial categories that are applied to the two APIs. Because monograph limits are updated periodically, the current USP, Ph. Int., Ph. Eur., or IP text must be consulted before batch disposition. The parameter values shown for assay and loss on drying are representative for pharmacopoeial-grade material and are not a substitute for the registered specification.

When Alternative Artemisinin-Based Combinations Require Different Formulation Approaches

Artemether–lumefantrine differs from other artemisinin-based combinations in partner-drug lipophilicity, dose ratio, food effect, and dosing schedule. Lumefantrine is more lipophilic than amodiaquine, and its oral bioavailability depends on coadministration with fat; the WHO treatment guideline for artemether–lumefantrine recommends administration with fatty food to increase systemic exposure. This food effect is not identical for every fixed-dose combination. Artesunate–amodiaquine is formulated as a co-formulated tablet with a higher aqueous solubility partner drug and is administered once daily for three days in many guidelines. Dihydroartemisinin–piperaquine is co-formulated with a partner drug that has a longer terminal half-life, allowing once-daily dosing for three days. In contrast, artemether–lumefantrine is administered twice daily for three days because lumefantrine half-life is approximately 3–6 days and the artemisinin component has an even shorter half-life. The 20:120 dose ratio also affects the formulation: artemether is a low-mass component that must be protected from segregation, while the higher-mass lumefantrine governs tablet hardness and disintegration time. Compared with artesunate injectable products, artemether injection is an oily intramuscular formulation, not an aqueous intravenous product. Therefore, the selection of an artemether–lumefantrine API grade is not interchangeable with the selection of artesunate, amodiaquine, or piperaquine; each combination has its own particle-size, dissolution, and processing requirements.

The product is supplied as separate artemether and lumefantrine API batches; it is not sold as a finished dosage form. The oral grade is suitable for tablet, capsule, and granule manufacture, and the injectable grade applies only to artemether. The product description should state the pharmacopoeial monograph, particle-size grade, residual solvent class, and pyrogen status for injectable artemether. Finished-dose manufacturers are responsible for process validation, dissolution method development, and regulatory submission. Specifications for artemether injection should include bacterial endotoxins under USP <85>, sterility under USP <71>, and particulate matter under USP <788>, while oral tablets, capsules, and granules are released for content uniformity, disintegration, dissolution, and microbial limits. This split between oral and injectable use is a critical difference from single-API antimalarial products and from other fixed-dose combinations in which both APIs are formulated only as oral solids.